Neoadjuvant chemotherapy in stage IB2 to IB3 cervical cancer: because we can or because we must?

IF 4.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

International Journal of Gynecological Cancer Pub Date : 2025-03-14 DOI:10.1016/j.ijgc.2025.101770

Philippe Morice, Sebastien Gouy, Marie Plante, Nadeem Abu-Rustum

引用次数: 0

查看原文本刊更多论文

IB2 至 IB3 期宫颈癌的新辅助化疗：因为我们可以还是因为我们必须？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Gynecological Cancer 医学-妇产科学

CiteScore

6.60

自引率

10.40%

发文量

280

审稿时长

3-6 weeks

期刊介绍： The International Journal of Gynecological Cancer, the official journal of the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research, reviews, and video articles. The audience consists of gynecologists, medical oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a special interest in gynecological oncology.